Investigation of Laser Assisted Drug Delivery of NanoDOX®
NCT: NCT05411484 · ACTIVE_NOT_RECRUITING
Brief Summary
This is a self-controlled single-site study of healthy subjects receiving an ablative fractional CO2 (carbon dioxide) laser procedure followed by topical application of NanoDOX® Hydrogel (1% doxycycline). The study includes skin biopsies to evaluate the effects of NanoDOX® Doxycycline Monohydrate Gel on wound healing after the ablative laser procedure. Study subjects will be asked to do 2 visits of 4 hours in total over approximately 1 week. An optional third visit will take place approximately 6 weeks after Visit 1. In this study, 20 subjects are expected to enroll with a goal of 12 healthy subjects to enroll and complete the study.
Frequently Asked Questions
What is Investigation of Laser Assisted Drug Delivery of NanoDOX®?
Investigation of Laser Assisted Drug Delivery of NanoDOX® is a clinical trial registered under NCT05411484. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT05411484?
The current status of NCT05411484 (Investigation of Laser Assisted Drug Delivery of NanoDOX®) is: ACTIVE_NOT_RECRUITING.
When did Investigation of Laser Assisted Drug Delivery of NanoDOX® start?
Investigation of Laser Assisted Drug Delivery of NanoDOX® started on 2023-11-29.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.